Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegorion is an osmotic laxative containing polyethylene glycol 4000 (macrogol 4000) without electrolytes, developed by Orion Corporation. It is indicated for the treatment of both acute and chronic constipation. The drug works through an osmotic mechanism, where the high molecular weight polymer retains water within the intestinal lumen. This increases stool volume and softens its consistency, which in turn stimulates colonic peristalsis and facilitates easier evacuation. Pegorion is specifically formulated without electrolytes (such as sodium or potassium salts), which can improve its taste profile and make it a suitable option for patients who need to limit their salt intake or who find electrolyte-containing solutions unpalatable. It is widely available as an over-the-counter medication in Finland and other European markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pegorion.